TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31701799
Drug: rosiglitazone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone with metformin (R + M)
Study: 25744509
Drug: High amylose
Normalized name: hydroxypropyl distarch phosphate, high amylose corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: High amylose maize resistant starch (RS) incorporated into fried wheat flour dough, given twice daily for 28 days.
Study: 24885993
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of transfluthrin coils and deltamethrin LLINs
Study: 30986735
Drug: Monoamine oxidase
Normalized name: Monoamine oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoamine oxidase inhibitors (MAOIs)
Study: 15169848
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ascorbic acid (500 mg day(‐1)) and RRR‐alpha‐tocopherol (400 i.u. day(‐1))
Study: 11489683
Drug: Bicalutamide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (150 mg daily)
Study: 7981579
Drug: Nicotine 0.014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 0.014 mg/kg body weight
Study: 7981579
Drug: Nicotine 0.028
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 0.028 mg/kg body weight
Study: 7981579
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg/kg body weight)
Study: 4666629
Drug: Intra-amniotic prostaglandin
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic prostaglandin F2α and intravenous oxytocin
Study: 27429113
Drug: Combined alfacalcidiol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined alfacalcidiol and metformin therapy (Group 2)
Study: 27429113
Drug: Metformin (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (Group 3)
Study: 23174632
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus glycoprotein IIb/IIIa inhibitor
Study: 20420643
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily calcineurin inhibitor (CNI) monotherapy at half their previous dose
Study: 20420643
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily calcineurin inhibitor (CNI) monotherapy
Study: 1651738
Drug: Low-dose ANP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ANP infusion (0.005 microgram/kg/min for 1 h)
Study: 1651738
Drug: High-dose ANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ANP infusion (0.05 microgram/kg/min for 1 h)
Study: 6341102
Drug: Ketotifen 2
Normalized name: ketotifen 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 2 mg daily per os
Study: 6341102
Drug: Oral disodium
Normalized name: etidronate disodium Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disodium cromoglycate
Study: 31210177
Drug: Tavipec® (Spicae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tavipec® (Spicae aetheroleum) 150 mg, 2 capsules thrice daily for 7 days
Study: 18812447
Drug: Sildenafil treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil treatment
Study: 23030673
Drug: Water ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water ingestion (50 mL)
Study: 23030673
Drug: Water ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water ingestion (500 mL)
Study: 17147487
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake (CI) in excess of 1039 mg/day
Study: 11927731
Drug: DTPa-HBV-IPV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-HBV-IPV vaccine coadministered with Hib vaccines (groups 1-4)
Study: 11927731
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available control vaccines (DTPa, Hib, and OPV) administered separately (group 5)
Study: 16709537
Drug: DTPa-HBV-IPV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-HBV-IPV vaccine
Study: 11927731
Drug: Hib N
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib N meningitidis outer-membrane complex protein conjugate vaccine
Study: 10216145
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy (9 million units three times a week for 38 +/- 8 weeks or 49 +/- 13 weeks)
Study: 10216145
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy (44.8 +/- 27.4 weeks)
Study: 8785887
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with calcipotriene
Study: 92202
Drug: Indirect treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect treatment away from the leak
Study: 25346345
Drug: Pivotal Response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pivotal Response Treatment Group (PRTG)
Study: 20020572
Drug: Lasofoxifene 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasofoxifene 0.5 mg
Study: 15231008
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 (500 IU/day) and calcium (500 mg/day) during winter months (October-April)
Study: 16684385
Drug: No supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplements (control group)
Study: 11420592
Drug: Suctioning techniques
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suctioning techniques (including preoxygenation, hyperinflation, insufflation, hyperoxygenation, hyperventilation, saline instillation, adaptor use, medication use, open and closed systems, and various types of catheters)
Study: 2870956
Drug: Terbutaline 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 0.25 +/- 0.25 mg iv
Study: 2870956
Drug: Prenalterol 1
Normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol 1 mg iv
Study: 2870956
Drug: Metoprolol 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 15 mg iv (pretreatment)
Study: 2870956
Drug: Propranolol 10
Normalized name: propranolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 10 mg iv (pretreatment)
Study: 2870956
Drug: Metoprolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol infusion
Study: 30074128
Drug: Prasugrel 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 2.5 mg/day
Study: 24808022
Drug: Corticosteroids alone
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids alone or in combination with cardioprotective medication
Study: 22825506
Drug: DC/CIK immunobiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC/CIK immunobiological cancer therapy
Study: 22825506
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no DC/CIK treatment)
Study: 16160068
Drug: Standard initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard initiation dose of 5 mg warfarin/day
Study: 16160068
Drug: Model-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model-based dosing using rapid CYP2C9 genotyping
Study: 16160068
Drug: Model-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model-based dosing
Study: 9049193
Drug: Norfloxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin, 400 mg daily administered orally (group 1)
Study: 3098141
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium cromoglycate (SCG) administered for 8 weeks
Study: 3098141
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered for 8 weeks
Study: 29678563
Drug: FIT Teens
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIT Teens (integrated Cognitive-Behavioral Therapy and specialized neuromuscular exercise training)
Study: 26896828
Drug: BIIB023 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB023 (3 or 20 mg kg(‐1) administered by intravenous infusion on Day 1)
Study: 23601577
Drug: 600-mg loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600-mg loading dose of clopidogrel 4 to 8 hours before PCI (n=122)
Study: 19081397
Drug: 600-mg loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600-mg loading dose of clopidogrel
Study: 14616928
Drug: naratriptan 2.5
Normalized name: naratriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naratriptan 2.5 mg
Study: 11833825
Drug: Intranasal influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal influenza vaccine (groups AI, AII, AIII)
Study: 11833825
Drug: Intramuscular virosomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular virosomal subunit vaccine (group B)
Study: 10073636
Drug: Control lenses
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Control lenses (subjects' own daily wear soft lenses)
Study: 7710021
Drug: Pre-operative measurement
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative measurement using paracetamol absorption technique
Study: 7710021
Drug: Post-operative measurement
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative measurement using paracetamol absorption technique
Study: 1975334
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg cromakalim
Study: 1975334
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg cromakalim
Study: 31760314
Drug: Erythrocyte-encapsulated asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythrocyte-encapsulated asparaginase (eryaspase) in combination with gemcitabine or mFOLFOX6
Study: 31760314
Drug: Erythrocyte-encapsulated asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy
Study: 19716144
Drug: Omegaven (4-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omegaven (4-hour lipid infusion contributing 0.04 g/kg of marine n-3 FA)
Study: 19716144
Drug: Intralipid (4-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid (4-hour lipid infusion)
Study: 17978709
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of antiplatelet therapy during surgery
Study: 17978709
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of antiplatelet therapy and substitution with flurbiprofen or isocoagulant fractionated heparin or calcium heparin
Study: 9205764
Drug: ebrotidine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ebrotidine 400 mg
Study: 9205764
Drug: ebrotidine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ebrotidine 400 mg (smokers)
Study: 9205764
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg (smokers)
Study: 8485019
Drug: BRL 46470A
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 46470A (0.1 microgram, 0.01 mg, 1 mg or 50 mg)
Study: 2889678
Drug: Procaterol 20
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol 20 mcg
Study: 2889678
Drug: Fenoterol 400
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol 400 mcg
Study: 12025709
Drug: Supplementary written
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary written drug information
Study: 12025709
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no supplementary written drug information)
Study: 7115656
Drug: Iron-folic acid
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-folic acid supplements (20 mg elemental Fe and 0.1 mg folic acid daily for 60 days)
Study: 7115656
Drug: Iron-folic acid
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-folic acid supplements (40 mg Fe and 0.2 mg folic acid daily in two divided doses for 60 days)
Study: 31272709
Drug: Fruquintinib 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 4 mg in fed state
Study: 28328324
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg per day adjusted to a maximum of 600 mg per day)
Study: 26321593
Drug: Inhaled epinephrine
Normalized name: epinephrine Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled epinephrine
Study: 17762286
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg triamcinolone
Study: 1991216
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg triamcinolone
Study: 16112241
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (LANTUS) at bedtime plus previous oral hypoglycaemic agents (OHAs)
Study: 16112241
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (LANTUS)
Study: 3298136
Drug: Busulfan (induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulfan (induction therapy)
Study: 18209510
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg twice a day)
Study: 17016190
Drug: Single-injection volar
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection volar subcutaneous block
Study: 17016190
Drug: Two-injection dorsal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-injection dorsal block
Study: 11012470
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg or Lansoprazole 30 mg taken 15 min before breakfast
Study: 11012470
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg or Lansoprazole 30 mg taken without a meal
Study: 8975939
Drug: UFT (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (300 mg/day) from 5th postoperative week for one year
Study: 8975939
Drug: Epirubicin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (40 mg/m2) bolus injection arterially on day 28, in addition to UFT administration
Study: 1335638
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (CLF strain, 360 ELISA units, 0.5 mg aluminium hydroxide)
Study: 1335638
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (HM175 strain, 180 ELISA units, 1 mg aluminium hydroxide)
Study: 1335638
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (HM175 strain, 360 ELISA units, 0.5 mg aluminium hydroxide)
Study: 1335638
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (HM175 strain, 360 ELISA units, 1 mg aluminium hydroxide)
Study: 1335638
Drug: Group E
Normalized name: Prostaglandin group E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group E (HM175 strain, 720 ELISA units, 1 mg aluminium hydroxide)
Study: 380631
Drug: Doxycycline (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (first treatment)
Study: 15936036
Drug: Sham infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham infusion
Study: 30791557
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g of Polydextrose per day
Study: 30791557
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g of Polydextrose per day
Study: 30791557
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of Polydextrose per day
Study: 27830395
Drug: Glutamine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (6 g/m2 per dose twice daily, maximum 10 g/dose)
Study: 15924620
Drug: High-intensity exercise
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity exercise program (twice weekly, one hour sessions for six weeks, performed at >= 60% of maximum heart rate)
Study: 12511367
Drug: IOP reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOP reduction achieved by medical, laser, or surgical therapy in OAG patients
Study: 12511367
Drug: IOP reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOP reduction achieved by medical, laser, or surgical therapy in OHT patients
Study: 1708961
Drug: Early suckling
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early suckling (treatment group)
Study: 373903
Drug: Mefloquine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (1.5 g)
Study: 373903
Drug: Pyrimethamine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine (75 mg) plus sulfadoxine (1.5 g)
Study: 27941065
Drug: Evolocumab (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (420 mg every 2 weeks)
Study: 29566128
Drug: Evolocumab (monotherapy)
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evolocumab (monotherapy)
Study: 29566128
Drug: Evolocumab (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (in combination with atorvastatin)
Study: 29566128
Drug: Evolocumab and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab and atorvastatin (substudy of 16 subjects)
Study: 24035299
Drug: Controlled temporary
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled temporary phrenic nerve palsy induced by local administration of lidocaine 1% at a rate of 3 mL/h (30 mg/h) via catheter.
Study: 12768300
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg, two times per day)
Study: 12768300
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue (goserelin 3.6 mg, every 28 days)
Study: 10376918
Drug: edrophonium HCl
DrugBank: Edrophonium (DB01010)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: edrophonium HCl (12 to 18 mg)
Study: 2066823
Drug: Poster intervention
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poster intervention group (weekly tracking with poster)
Study: 2066823
Drug: Poster/postcard intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poster/postcard intervention group (weekly tracking with poster and postcard reminders)
Study: 6799196
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) during ProMACE-MOPP treatment
Study: 6799196
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet during ProMACE-MOPP treatment
Study: 6799196
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) as an adjunct to chemotherapy or chemotherapy plus total body irradiation
Study: 6799196
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet as an adjunct to chemotherapy or chemotherapy plus total body irradiation
Study: 31941354
Drug: Intravenous Amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Amiodarone
Study: 30004914
Drug: Intravenous Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Lidocaine
Study: 31941354
Drug: Intravenous Drugs
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Drugs (Amiodarone or Lidocaine)
Study: 31941354
Drug: Intraosseous Drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous Drugs (Amiodarone or Lidocaine)
Study: 31941354
Drug: Placebo (Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Intravenous and Intraosseous)
Study: 10325486
Drug: 0.1% adapalene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% adapalene gel
Study: 26226999
Drug: Ranolazine 750
Normalized name: Ranolazine 750 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 750 mg BID and Dronedarone 225 mg BID
Study: 26226999
Drug: Ranolazine 750
Normalized name: Ranolazine 750 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 750 mg BID and Dronedarone 150 mg BID
Study: 26226999
Drug: Ranolazine alone
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine alone (750 mg BID)
Study: 26226999
Drug: Dronedarone alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone alone (225 mg BID)
Study: 22229650
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with propofol and remifentanil
Study: 19208440
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate and GTN spray (group A)
Study: 19208440
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug and GTN spray (group B)
Study: 19208440
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate and placebo spray (group C)
Study: 19208440
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug and placebo spray (group D)
Study: 17890876
Drug: Intravenous EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous EPO
Study: 17163894
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of providing information and behavioral skills training
Study: 9278201
Drug: Prednisolone and
Normalized name: prednisolone and mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone and Niacin combination